---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-063884"
form_type: "8-K"
ticker: "ELOX"
cik: "0001035354"
company_name: "Eloxx Pharmaceuticals, Inc."
filed_at: "2023-05-24T23:59:59+00:00"
generated_at: "2026-06-14T15:31:37.596805+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Eloxx reports ELX-02 Phase 2 topline: one patient remission; opens $50M ATM offering

## Summary
- One of two completed patients achieved remission (≥50% UPCR decline); five of eight readings averaged 53% below baseline.
- Second patient showed no significant UPCR change; both had same Col4A4 mutation but different RAAS inhibitor levels.
- ELX-02 generally well tolerated; no discontinuations; kidney biopsies showed no nephrotoxicity.
- Entered ATM agreement with Oppenheimer for up to $50M common stock sales, currently limited to $6.5M due to S-3 limits.
- Prior SVB Leerink ATM agreement terminated; no shares were sold under that agreement.

## SEC filing metadata
- accession: 0001104659-23-063884
- form_type: 8-K
- ticker: ELOX
- cik: 0001035354
- company_name: Eloxx Pharmaceuticals, Inc.
- filed_at: 2023-05-24T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 1.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1035354/000110465923063884/0001104659-23-063884-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1035354/000110465923063884/tm2316480d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-063884
- JSON: https://secwatch.observer/filing/0001104659-23-063884.json
- Plain text: https://secwatch.observer/filing/0001104659-23-063884.txt

## Key facts
- Material Agreements
  Eloxx Pharmaceuticals, Inc. terminated SVB Sales Agreement with SVB Leerink LLC (effective 2023-05-24).
  - Action: termination
  - Agreement: atm program
  - Counterparty: SVB Leerink LLC
  - Effective: 2023-05-24
  source text: nto a Sales Agreement (the “SVB Sales Agreement”) with SVB Leerink LLC (“Cowen”) to sell shares of the Company’s Common Stock with aggregate gross sales proceeds of up to $50 million, from time to time, through an “at the market” equity
  evidence_url: https://www.sec.gov/Archives/edgar/data/1035354/000110465923063884/0001104659-23-063884-index.htm
- Material Agreements
  Eloxx Pharmaceuticals, Inc. entered into Oppenheimer Sales Agreement with Oppenheimer & Co. Inc. valued at aggregate gross sales proceeds of up to $50.0 million (effective 2023-05-24).
  - Action: entry
  - Agreement: atm program
  - Counterparty: Oppenheimer & Co. Inc.
  - Value: aggregate gross sales proceeds of up to $50.0 million
  - Effective: 2023-05-24
  source text: On May 24, 2023, Eloxx Pharmaceuticals, Inc. (the “Company”) entered into a Sales Agreement (the “Oppenheimer Sales Agreement”) with Oppenheimer & Co. Inc. (“Oppenheimer”) pursuant to which the Company may offer and sell shares of its common stock, par value $0.01 per share (the “Common Stock”), having aggregate gross sales proceeds of up to $50.0 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1035354/000110465923063884/0001104659-23-063884-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.